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ABSTRACT Using replica exchange molecular dynamics simulations and the implicit solvent model we probed binding of
ibuprofen to Ab10–40 monomers and amyloid ﬁbrils. We found that the concave (CV) ﬁbril edge has signiﬁcantly higher binding
afﬁnity for ibuprofen than the convex edge. Furthermore, binding of ibuprofen to Ab monomers, as compared to ﬁbrils, results in
a smaller free energy gain. The difference in binding free energies is likely to be related to the presence of the groove on the CV
ﬁbril edge, in which ibuprofen tends to accumulate. The conﬁnement effect of the groove promotes the formation of large low-
energy ibuprofen clusters, which rarely occur on the surface of Ab monomers. These observations led us to suggest that the
ibuprofen binding mechanism for Ab ﬁbrils is different from that for monomers. In general, ibuprofen shows a preference to
bind to those regions of Abmonomers (amino terminal) and ﬁbrils (the CV edge) that are also the primary aggregation interfaces.
Based on our ﬁndings and on available experimental data, we propose a rationale for the ibuprofen antiaggregation effect.doi: 10.1016/j.bpj.2009.07.032INTRODUCTION
Aggregation of polypeptide chains and formation of amyloid
fibrils are associated with the development of a number of
disorders, including Alzheimer’s, Parkinson’s, type II dia-
betes, and Creutzfeldt-Jakob disease (1). Amyloid assembly
generally proceeds through a complex sequence of structural
transitions, which starts with the oligomerization of mono-
meric chains and eventually leads to the formation of amy-
loid fibrils (2). Experimental data indicate that oligomers,
even as small as dimers, appear to be the primary cytotoxic
species (3–6). Because amyloid fibrils are reservoirs of
monomers, they may play an important role in the dynamic
equilibrium of soluble oligomeric species (7–9). The hall-
mark of fibril internal organization is an extensive b-sheet
structure (10–14). Backbone hydrogen bonds and a host of
side-chain interactions lend considerable stability to amyloid
fibrils against dissociation (15).
Aggregation of Ab peptides (Fig. 1, a–c), which are the
natural products of cellular proteolysis, is linked to
Alzheimer’s disease (AD). The most abundant Ab species
are 40-mer peptides (Ab1–40). The structure of fibril protofila-
ment for these peptides has been recently derived from solid-
state NMR experiments (12) (Fig. 1 c). This structure reveals
parallel in-registry b-sheets formed byAbmonomers (11,13).
Given the apparently critical role of Ab peptides in AD
pathogenesis, it is important to find molecular agents that
make it possible to control Ab aggregation. One of the prom-
ising candidates is the nonsteroidal antiinflammatory drug
ibuprofen (16). Biomedical studies suggest that treatment
with ibuprofen reduces the amount of Ab deposits and
alleviates memory deficits in mice models (17,18). Ibuprofen
intake also correlates with a decrease in the amount of Ab
oligomers in mice brain tissues (18). A prophylactic long-
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0006-3495/09/10/2070/10 $2.00term use of ibuprofen appears to reduce the risk of AD
(19), but the effectiveness of this drug against preexisting
AD cases is unclear (20). Several recent experimental studies
have investigated the molecular aspects of interactions
between Ab and ibuprofen. Binding of ibuprofen to Ab
fibrils has been demonstrated when the ligand/peptide
stoichiometric ratio approximates or exceeds 1 (21,22).
Experimental in vitro studies have shown that ibuprofen
reduces accumulation of Ab fibrils by apparently interfering
with fibril elongation (23). Furthermore, ibuprofen demon-
strates an ability to at least partially dissociate preformed
Ab fibrils (21,23).
Despite progress in experimental observations, there are
still many questions about Ab-ibuprofen interactions on
a molecular level. For example, 1), where are the ibuprofen
binding sites in Ab peptides and what are the physicochem-
ical factors controlling ibuprofen binding? 2), Are there
differences in binding affinity among the different Ab
species, such as monomers or fibrils? 3), Does ibuprofen
binding induce changes in Ab peptide structure? Answering
these questions will be important to our understanding of the
mechanism of Ab fibril dissociation induced by ibuprofen
and may aid in designing new antiaggregation agents.
All-atom computer simulations, such as molecular
dynamics (MD), are well suited to provide molecular-level
details of Ab-ibuprofen interactions (24). In recent years,
MD has been used to map the pathways of fibril growth
(25–30), to investigate the conformational ensembles of amy-
loidogenic peptides (31–34), and to assess the energetics of
fibril structures (35–38). However, molecular simulations of
amyloidogenic peptides coincubatedwith ligands are still rela-
tively rare. Binding of the fluorescence dye thioflavin T (ThT)
to the fibrils formed by Ab fragments, Ab16–22, has been
probed using all-atom MD (39). Two ThT binding sites were
identified, one in the hydrophobic groove on the fibril side
and another on the fibril edge. From MD simulations, the
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FIGURE 1 (a) Sequence of Ab10–40 monomer and the
allocation of the N- and C-terminals (also referred to as
b1 and b2 strands). (b) Representative snapshot of Ab10–40
monomer with bound ibuprofen molecules. The N- and
C-terminals are shown in red and orange, respectively.
The N-terminal has a higher binding affinity than the
C-terminal. (c) Cartoon representation of Ab10–40 fibril
fragment formed by four peptides, F1 and F2 (orange),
and F3 and F4 (red), with bound ibuprofen molecules.
The fibril protofilament consists of four laminated in-
registry b-sheets formed by the b1 and b2 strands in the
Ab peptide portrayed in a. The stagger of inner b2 sheets
with respect to b1 sheets results in the appearance of two
distinct fibril edges, a concave (CV) and a convex (CX)
edge. On the CV edge, indented b2 sheets form a groove.
The CX and CV edges are formed by the peptides F1 and
F2, and F3 and F4, respectively. Compared to the CX
edge, the CV edge has a higher binding affinity for
ibuprofen. As a result, ligands tend to localize on the CV
edge, forming large clusters in the groove. (d) An ibuprofen
molecule showing the atoms with their notations, which are
explicitly represented in the CHARMM19 force field (see
the Supporting Material for ibuprofen parameterization).
Also shown are the structural groups G1–G3 (dashed
circles) and dihedral angles c1 and c2.binding energetics for ThTwas also computed.More recently,
binding of tricyclic planar ligands (9,10-anthraquinone and
anthracene) to fibril formingAb fragments Ab14–20 was inves-
tigated using MD (40). The results showed that 9,10-anthra-
quinone interferes with the formation of interstrand hydrogen
bonds and reduces the accumulation of ordered aggregates.
However, to the best of our knowledge, MD studies of
ibuprofen binding to Ab have not been performed.
In this article, we address the three questions posed above
using the atomistic implicit solvent model and replica
exchange molecular dynamics (REMD) (41). By conducting
separate simulations, we investigate the binding of ibuprofen
molecules to Ab monomers and to experimentally deter-
mined structures of Ab fibrils. These two systems have
been selected because monomers and fibrils represent the
initial and final products in the Ab amyloidogenic pathway.
Extensive sampling in a wide range of temperatures allowed
us to compute thermally weighted distributions of ibuprofenmolecules in the vicinity of Ab monomers and fibrils and
to compare their binding free energies. On the basis of




Simulations of Ab peptides and ibuprofen (Fig. 1) were performed using the
CHARMM MD program (42) and the atomistic force field CHARMM19
coupled with the solvent-accessible surface area (SASA) implicit solvent
model (43). A detailed description of this model, as well as its applicability
and testing, can be found in our previous studies (44,45). In particular, the
CHARMM19þSASA force field has been shown to reproduce well the
experimental distribution of chemical shifts for Ca and Cb atoms (45). Param-
eterization of ibuprofen (Fig. 1 d) was performed consistent with the
CHARMM19 force field, SASA solvation parameters, and taking into
account the similarity of ibuprofen structure to that of Leu, Phe, and Asp
side chains. Because the pKa value for ibuprofen is 4.5, the polar groupBiophysical Journal 97(7) 2070–2079
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solvent model, was set neutral to prevent excessive stability of salt bridges
(43). The complete list of ibuprofen force-field parameters is given in the Sup-
porting Material. Testing of ibuprofen parameterization is reported below.
We consider two simulation systems: 1), Ab10–40 monomer interacting
with Nibu ¼ 10 ibuprofen molecules; and 2), the fibril fragment formed by
four Ab10–40 peptides interacting with Nibu ¼ 40 ibuprofen molecules. In
both systems, we used N-terminal truncated Ab peptides as a model of
the full-length Ab1–40 (34). Further description of the simulation systems
is provided in the Supporting Material and in our previous studies (34,44).
The Ab peptide/ibuprofen concentration ratio is 1:10, which is only slightly
higher than that used experimentally (21,23). Throughout this article, the
peptides in Fig. 1 c are referred to as fibrils.
Replica exchange simulations
Conformational sampling was performed using REMD (41). This method
makes it possible to achieve exhaustive sampling of rugged free-energy
landscapes and has been applied to study protein folding and aggregation
(26,30,46–49). The details of REMD implementation and its convergence
are discussed in the Supporting Material.
Computation of structural probes
The intrapeptide interactions and those between Ab peptides and ibuprofen
were probed by computing the number of side-chain contacts and hydrogen
bonds (HBs). A side-chain contact was considered formed if the distance
between the centers of mass of side chains is <6.5 A˚ (50). Computation
of contacts formed by ibuprofen molecules is described in the Supporting
Material.
Intrapeptide backbone HBs between NH and CO groups were assigned
according to Kabsch and Sander (51). The same definition was applied to
detect HBs between hydrophilic groups G3 in ibuprofen and peptide back-
bone NH groups. Secondary structure in Ab peptides was assigned based on
the distribution of backbone dihedral angles (f and j). Specific details
concerning the definitions of b-strand and helix states can be found in a
previous publication (45). Throughout this article, angular brackets <.>
imply thermodynamic averages. Unless stated otherwise, all quantities
related to ibuprofen represent the averages over all ibuprofen molecules.
The distributions of states produced by REMD were analyzed using the
multiple histogram method (52).
Testing force ﬁeld parameterization of ibuprofen
Recently, a conformational analysis of ibuprofen was performed using
density functional theory and verified by optical vibrational spectroscopy
(53). From this analysis, the distributions of two dihedral angles, c1 and
c2 (Fig. 1 d), became available, which offers us an opportunity of testing
CHARMM19 ibuprofen parameterization. The testing results can be found
in the Supporting Material.
RESULTS
Guided by the allocation of secondary structure in experi-
mental fibril structure (12) (Fig. 1, a and c), we distinguish
two sequence regions in Ab10–40: the N-terminal (NT, resi-
dues 10–23), corresponding to the first fibril b-strand, b1,
and the C-terminal (CT, residues 29–39), corresponding to
the second fibril b-strand, b2.
Binding of ibuprofen to Ab monomers
As described in Methods, we used REMD and the implicit
solvent model to probe the interactions of ibuprofen mole-Biophysical Journal 97(7) 2070–2079cules with Ab10–40 monomers (Fig. 1 b). We first computed
the thermal probability of an ibuprofen molecule binding to
Ab (Pb) as a function of temperature. Fig. 2 shows that
at T ( 310 K, Pb(T) > 0.5, indicating that ibuprofen
bound states are thermodynamically preferred. Conse-
quently, the binding temperature (Tb) is assumed to be
~310 K. Because it is close to physiological temperature,
the thermodynamic quantities for Ab monomer are reported
at Tb. The total number of ibuprofen molecules bound to Ab
at 310 K is <L> ¼ NibuPb z 4.9 (Fig. 2, inset). The inset
also shows the number of ibuprofen molecules, <Lh(T)>,
bound to Ab by forming hydrophobic interactions. Because
at 310 K <Lh>z 3.3 ¼ 0.67<L>, we conclude that about
two-thirds of ligands utilize hydrophobic interactions for
binding.
Fig. 3 shows the numbers of contacts with ibuprofen
formed by individual side chains of residues i in Ab mono-
mer, <Cl(i)>. Although there are significant variations in
<Cl(i)> between neighboring residues, one can discern
a tendency for the N-terminal to form a large number of
contacts with ibuprofen. Indeed, on average, the N-terminal
forms <Cl(NT)> z 10.9 contacts with ibuprofen (or 0.8/
residue). In contrast, the number of contacts between the
C-terminal and ibuprofen is <Cl(CT)> z 4.8 (or 0.4/
residue). Therefore, the N-terminal forms about twice
as many interactions with ibuprofen compared to the
C-terminal. The total number of side-chain contacts with
ibuprofen, <Cl>, is ~18.4. Because the number of ligands
bound to Ab, <L>, is ~4.9, each ligand interacts with about
<Cl>/<L> z 3.8 amino acids. These calculations suggest
that as a rule, each bound ibuprofen molecule forms contacts
with multiple amino acids.
FIGURE 2 Probability of an ibuprofen molecule binding to an Ab mono-
mer as a function of temperature (Pb(T)). The dashed line marks Pb ¼ 0.5.
(Inset) Temperature dependence of the average number of ligands bound
to Abmonomer,<Lh>, via hydrophobic interactions (gray curve) compared
with the total number of bound ibuprofen molecules, <L(T)> (black curve).
At temperatures <310 K, the ibuprofen bound state is thermodynamically
preferred.
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interactions and backbone HBs to binding energetics. Fig. S3
in the Supporting Material shows the number of HBs,
<Nlhb(i)>, formed between the backbone NH groups of
amino acids i and the oxygen atoms in the ibuprofen group
G3 (Fig. 1 d). Except for the few N-terminal residues
<Nlhb(i)> < 0.05. From Fig. S3, we determine that the total
number of HBs formed between ibuprofen and peptide
backbone is <Nlhb> z 1.6. Because <Nlhb> is more than
10 times smaller than the number of contacts between
ibuprofen and side chains, <Cl>, the contribution of HBs
to binding is small.
Next, we evaluate the impact of ibuprofen binding on the
conformational ensemble of Ab monomer. To this end, we
compare the fractions of b-strand, <S>, and helix, <H>,
structure formed by Ab10–40 monomers in water and in
ibuprofen solution. The distribution of Ab10–40 secondary
structure in water has been investigated in previous studies
(34,45). Fig. S4 in the Supporting Material shows the
ibuprofen-induced changes in b-strand (<DS(i)>) and helix
(<DH(i)>) structures formed by residues i. These plots reveal
small but systemic conversion of helix into strand structure.
The average change in the fraction of residues in b-strand
conformations is <DS> ¼ <Sibu>  <Sw>z 0.06, where
<SW> (~0.16) and <Sibu> (~0.21) are the b-strand fractions
in water and ibuprofen solution, respectively. The helix
fraction reveals a small decrease (<DH> z 0.04), from
<HW> z 0.38 in water to <Hibu> z 0.34 in ibuprofen
solution. However, the fraction of random coil structure
remains unchanged within computational error (0.46 in water
versus 0.45 in ibuprofen solution). Therefore, the impact of
ibuprofen binding on secondary structure of Ab monomer
FIGURE 3 Number of contacts with ibuprofen, <Cl(i)>, formed by side
chains of residues i in Ab monomer. The black line represents <Cl(i)>
smoothed with the sliding window of three residues, and the gray line shows
accessible surface area <ASA(i)> of amino acids i (also smoothed with the
sliding window of three residues). The plot implies that ibuprofen primarily
binds to the N-terminal of Ab monomers. The data are computed at 310 K.
To compute ASA, the probe radius was set to 3.2 A˚, which corresponds to
the average radius of gyration of ibuprofen molecules.appears to be weak and the peptide retains mostly random
coil conformations augmented by significant helix and strand
contents. In the Supporting Material, we also show that
ibuprofen causes minor changes in the radius of gyration of
Ab monomer (Fig. S5).
Binding of ibuprofen to Ab ﬁbrils
To explore binding of ibuprofen to Ab10–40 fibrils (Fig. 1 c),
we utilized a strategy similar to that used for Ab10–40 mono-
mers. Using REMD, we computed the temperature depen-
dence of the binding probability, Pb(T), for the ibuprofen
molecule. Fig. 4 shows that the midpoint of Pb(T) corre-
sponds approximately to T ¼ 362 K, which is identified
as the binding temperature, Tb. Therefore, bound ibuprofen
states are stable at T < Tb. It is important to note that,
compared to Ab10–40 monomers, the fibril Tb is higher by
~50 K. Below, the binding properties of ibuprofen are
reported at 330 K, the closest temperature to physiological
conditions, for which REMD sampling is available.
The binding probability, Pb, does not distinguish peptides
or edges in the fibril. To map the distribution of ibuprofen
molecules on the fibril surface,we considered twofibril edges,
the convex (CX) and concave (CV), formed by the peptides
F1 and F2, and F3 and F4, respectively (Fig. 1 c). The
numbers of ligand molecules bound to the CX and CV
edges as a function of temperature are presented in the inset
to Fig. 4. This plot indicates that at T < Tb, there is a prefer-
ence for ibuprofen molecules to bind to the CV edge.
For example, at 330 K, the number of ligands bound to the
CV is <L(CV)> z 22.1, whereas for the CX edge it is
<L(CX)> z 15.2. The inset also shows the numbers of
FIGURE 4 Probability of ibuprofen molecules binding to Ab fibrils as
a function of temperature, Pb(T). The dashed line marks Pb ¼ 0.5. (Inset)
Numbers of ibuprofen molecules, <L(CV)> (black line) and <L(CX)>
(gray line), bound to the CV and CX edges, respectively, versus tempera-
ture. The numbers of ligands bound to the CV (<Lh(CV)>; gray line) and
CX (<Lh(CX)>; gray line) edges via hydrophobic interactions are also
plotted. At temperatures (362 K, the ibuprofen bound state is thermody-
namically preferred, and most ligands are found on the CV edge.Biophysical Journal 97(7) 2070–2079
2074 Raman et al.ibuprofen molecules, <Lh(CV)> and <Lh(CX)>, bound to
the CV and CX fibril edges via hydrophobic interactions.
Although significantly smaller, <Lh(CV)> and <Lh(CX)>
follow the same temperature dependence as <L(CV)> and
<L(CX)>. At 330 K, <Lh(CV)> and <Lh(CX)> are ~11.8
and ~8.1, respectively. Thus, approximately half of all ligands
are bound to the fibril through hydrophobic interactions.
To get further insight into the binding mechanism, we
computed the number of contacts <Cl> formed between
ligands and the side chains on fibril edges. On average, the
CX and CV edges form <Cl(CX)>z 47.0 and <Cl(CV)>
z 69.8 contacts with ibuprofen. Taking into account that the
CX (CV) edge binds ~15.2 (22.1) ligands, we surmise that
a bound ibuprofen molecule interacts with about three amino
acids at once. We also obtained the numbers of HBs formed
between the CX and CV peptide backbones and ibuprofen,
<Nlhb(CX)> and <Nlhb(CV)>. At 330 K, <Nlhb(CX)> z
6.2, whereas <Nlhb(CV)> z 5.5. Therefore, the number
of side-chain contacts exceeds the number of HBs eightfold
on the CX edge and 13-fold on the CV edge. As in the case of
Ab monomer, binding of ibuprofen to Ab fibril is mainly
driven by side-chain interactions.
The findings reported above suggest that the CV edge has
a higher affinity for ibuprofen than does the CX edge. This
result can be illustrated by computing the spatial distributionBiophysical Journal 97(7) 2070–2079of ligands, P(z), along the fibril axis, z (Fig. 5 a). It follows
from this distribution that the fractions of ligands bound to
the CV and CX edges are 0.55 and 0.29, respectively. The
probability of binding to the fibril side (Fig. 5 a) is very
low (0.03) and is ~30 times smaller than the combined prob-
ability of edge binding (see Discussion).
It is also important to map the spatial distributions of
ibuprofen on two fibril edges. To this end, we considered
two distributions, PCX(y) and PCV(y), which are computed
for the CX and CV edges along the y axis perpendicular to
the fibril axis (Fig. 1 c). Fig. 5 b demonstrates that PCX(y)
and PCV(y) have different profiles, reflecting distinct geome-
tries of the edges. Because the b2 strands are protruding
on the CX edge, PCX(y) shows two poorly defined maxima
at þ10 A˚ and 10 A˚, approximately corresponding to the
gaps between the b1 and b2 sheets (Fig. 1 c). In contrast, a
single maximum of large amplitude is observed in PCV(y),
corresponding to the location of the groove formed by
indented b2 sheets on the CV edge. Therefore, upon binding
to the CV edge, ibuprofen tends to localize within the
groove.
It is instructive to directly visualize the observations made
based on PCV(y) and PCX(y) in Fig. 5 b. To this end, we
computed the fibril surface area accessible to ibuprofen
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FIGURE 5 (a) Probability distribution for the position of ibuprofen center of mass along the fibril axis z, P(z). To estimate the probabilities of binding, we
assume that the ligand is located on the CX edge if15 A˚< z<3 A˚, on the CV edge if 3 A˚< z< 17 A˚, and on the fibril side if3 A˚< z< 3 A˚. The shaded
area approximately marks the maximum extent of fibril fragment. (b) Probability distributions, P(y), (shaded area) for the center-of-mass position of ibuprofen
along the y axis perpendicular to the fibril axis. The left and right panels are computed for the CX (z < 0) and CV (z > 0) edges, respectively. The plots also
show the smoothed projections of the edge surfaces on the yz plane (black lines, see also Fig. 1 c). The edge surface is represented by the side-chain centers of
mass. (c) The surfaces of the CV and CX edges accessible to ibuprofen computed using a probe radius of 3.2 A˚ (ibuprofen radius of gyration). The surfaces of
residues i in peptides k are color-coded according to the number of side-chain contacts<Cl(i;k)> they form with ibuprofen at 330 K: red, gray, and blue corre-
spond to large, medium, and small <Cl(i;k)> values, respectively. (Although the fibril pictured in c and used in a and b corresponds to the energy-minimized
structure, it serves as a good representation of the thermally weighted fibril surface. For example, the correlation between the water ASA(i) for the energy-
minimized structure and that computed at 330 K is >0.95). The probability distributions in a–c, computed at 330 K show that ibuprofen primarily binds
to the CV edge and localizes within the groove on its surface.
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be seen from Fig. 5 c that the amino acids showing a large
number of interactions with ibuprofen are those in the CV
groove (or on its rim), and especially those protruding
from the groove surface. To determine ibuprofen binding
sites, we operationally selected amino acids i in peptides
k ¼ F3,F4 for which the number of contacts with ibuprofen
<Cl(i;k)> is no less than 70% of the maximum (i.e.,
<Cl(i;k)> R 0.7 max i,k{<Cl(i;k)>}). With this definition,
ibuprofen binding sites include Gln15(F3), Gly29(F3),
Ile31(F3), Met35(F3), Val39(F3), Glu11(F4), Gln15(F4),
Phe19(F4), and Val40(F4). The list includes both hydro-
phobic and hydrophilic amino acids and appears to imply
that ibuprofen binding is mainly driven by fibril surface
geometry rather than by physicochemical properties of indi-
vidual residues. Using the same definition, we found that
the CX edge binding sites involve only three amino acids:
Ser26(F1), Ala30(F1), and Ile32(F1) (Fig. 5 c). (Setting the
net charge of ibuprofen to zero in the CHARMM19 force
field might affect its binding to the fibril. However, it is
unlikely that the neglect of ibuprofen charge qualitatively
changes the binding to the fibril, because only 1 of 12 amino
acids identified as primary binding sites is charged.)
Binding free energy
There are some indications from experimental studies that as
a ligand, ibuprofen selectively ‘‘recognizes’’ Ab fibrils
among other structural species (see Discussion) (54). To
check this possibility, we used REMD to compute the free
energies of ibuprofen binding to Ab monomers and fibrils.
Fig. 6 displays the free energies of ibuprofen molecules,
F(rb), as a function of the distance, rb, between the ligand
ΔFbm/RT
ΔFbf/RT
FIGURE 6 Free energy of an ibuprofen molecule, F(rb), as a function of
the distance, rb, between the ligand and the surface of Ab monomers (solid
circles) or fibrils (open circles). Free-energy profiles, F(rb), reveal that
binding to fibrils is thermodynamically preferred. The free energy, F(rb),
is obtained at 330 K using all binding states of all the ligands that are popu-
lated at this temperature; the free energy at rb > 20 A˚ is set to zero.and the surface of the monomer or fibril. The two free-energy
profiles are qualitatively similar and show a single minimum
at rb, 0z 5 A˚. From Fig. 6, the binding free energy can be
defined as DFb ¼ F(rb, 0) – F(rb > 20). Using this definition,
we determine that DFb
m for the monomer and DFb
f for the
fibril are 3.7RT and 5.9RT, respectively. This result
implies that fibril-bound ibuprofen states are more stable
(by ~2.2RT) than monomer-bound states.
DISCUSSION
In this study, we used REMD and an atomistic model to
investigate ibuprofen binding to Ab monomers and fibrils.
Consistent with experiments (21,23), we observed that at
low enough temperatures, ibuprofen binds to Ab species
and that binding to Ab fibrils is thermodynamically preferred
over binding to monomers. By analyzing the distribution of
ligands on the surface of Ab monomers and fibrils, we
located the putative binding sites. These observations raise
two questions: 1), What are the physicochemical factors
that control ibuprofen binding? and 2), Can we use the
results of REMD simulations to explain the antiaggregation
effect observed experimentally for ibuprofen?
Cooperativity of ibuprofen binding to Ab ﬁbril
To provide some tentative answers to the questions above,
we analyzed the distribution of clusters formed by bound
ligands on the surface of Ab fibrils at 330 K. A bound
cluster is defined as an isolated group of ibuprofen molecules
bound to the fibril edge that do not form contacts with other
bound ligands (see Methods). The size of a cluster, Sc, is
given by the number of ibuprofen molecules included. Using
REMD, we computed the distributions of bound ligands,
<L(Sc)>, where <L(Sc)> is the thermally averaged number
of molecules in a cluster of size Sc. Of particular interest is
the distribution <L(Sc)> for the CV fibril edge (Fig. 1 c).
This distribution (shown in Fig. S6 a) is bimodal, featuring
two maxima at Sc ¼ 1 and 22. If we assume that coopera-
tively bound ligands comprise the clusters with Sc > 6,
then their number is <Lcl(CV)> z 17.8 z f<L(CV)>,
where <L(CV)> z 22.1 is the total number of ibuprofen
molecules bound to the CV edge and f z 0.81. The distri-
bution <L(Sc)> for the CX edge is qualitatively different.
Fig. S6 b reveals one maximum in <L(Sc)> at Sc ¼ 1 and
the distribution is generally skewed toward small Sc (e.g.,
<Lcl(CX)> is only ~6.0). Consequently, f for the CX
edge is 0.40.
Further analysis suggests that the formation of large clus-
ters on the CV edge reduces the average effective energy,
Eeff, of the simulation system, which includes potential
and solvation energies. Specifically, when all ligands bound
to the CV edge are organized into large clusters (Sc> 6), Eeff
is DEeff z 19 kcal/mol lower than the energy of the states,
which have only small clusters (Sc % 6). It is of interestBiophysical Journal 97(7) 2070–2079
2076 Raman et al.that similar computations for the CX edge show no decrease
in Eeff upon formation of large ibuprofen clusters.
We have reported that the number of ligands bound to
the CV edge, <L(CV)>, exceeds that on the CX edge,
<L(CX)>, by a factor of 1.5. The analysis presented above
suggests a rationale for the preference of ibuprofen mole-
cules for binding to the CV edge. The distributions <L(Sc)>
demonstrate that large clusters of bound ligands frequently
appear on the CV edge, but are relatively rare on the CX
edge. According to Fig. 5, b and c, most ibuprofen molecules
bound to the CV are localized within the groove. It is then
reasonable to suggest that this geometrical feature of Ab
fibrils facilitates the formation of large ibuprofen clusters
due to a ‘‘confinement’’ effect of the groove. As shown
above, the formation of large clusters tends to reduce the
energy of the system. Because the CX edge has no groove,
such an effect is not observed, and the affinity of the CX
edge is low compared to that of the CV edge. The conclusion
that the binding surface geometry determines ligand binding
finds support in simulations of structurally modified fibril
(Supporting Material). By eliminating the CV groove and
enhancing the small grooves on the CX edge, the affinity
of the ‘‘new’’ CX edge becomes as strong as the affinity of
the ‘‘wild-type’’ CV edge (Fig. S7).
Therefore, the geometry of the binding surface appears
to be more important for ibuprofen association with Ab
fibrils than specific sequence composition or accessible
surface area (ASA). (We observed no correlation between
the number of contacts ibuprofen forms with side chains,
<Cl(i;k)>, and ibuprofen ASA of amino acid i in peptide
k,<ASA(i;k)>.) This conclusion is supported by the mixture
of residue types involved in ibuprofen binding sites. Further-
more, a relevant observation has been made in experiments
on the ligand-induced dissociation of fibrils formed by Ab
and a-synuclein polypeptides (23,55). In these experiments,
nine different antiaggregation ligands, including ibuprofen,
were evaluated for their dissociation efficiency. It is
intriguing that the order of their antiaggregation efficiency
remains the same for both polypeptides, even though their
sequence similarity is low (9%). This observation suggests
that the sequence composition may not be the leading factor
in ligand binding. It is important to note that the grooves on
the fibril surface represent the primary binding sites for other
ligands. For example, scanning tunneling microscopy exper-
iments have shown that ThT dye is localized in the grooves
formed on the surface of Ab42 fibril-like aggregates (56). A
similar conclusion has been reached in a recent MD study
(39). These reports are consistent with our finding that the
CV groove is a primary binding location for ibuprofen.
According to our REMD simulations, side-chain interac-
tions with ibuprofen, rather than backbone HBs, play a major
role in ligand binding to Ab. According to the analysis of
fibril (and monomer) binding, the number of side-chain
contacts with ibuprofen exceeds the number of HBs between
peptide backbone and the ligand ~10-fold.Biophysical Journal 97(7) 2070–2079Finally, it is instructive to comment on ibuprofen binding
to the fibril sides. The small size of the fibril fragment we
studied may artificially suppress the probability of fibril
side binding. However, we believe that this limitation is
not crucial, because it is the binding sites on the fibril edges
that are apparently responsible for the ibuprofen antiaggrega-
tion effect. As discussed below, the edges appear to represent
the fibril elongation interface.
Factors controlling ibuprofen binding to Ab
monomers
The distribution of ibuprofen molecules, <L(Sc)>, bound to
Ab monomer does not resemble that seen on the CV fibril
edge, but is qualitatively similar to that on the CX edge
(data not shown). For example, the fraction of ligands
confined to large bound clusters, f, is only 0.1, and the distri-
bution, <L(Sc)>, is unimodal at 310 K. The absence of
stable structural pockets or grooves in the monomer devoid
of stable native fold is likely to disfavor the formation of
large ligand clusters. This circumstance is expected to limit
the free-energy gain that occurring upon ibuprofen binding
to Ab monomers relative to the fibrils. As demonstrated
above, compared to binding to monomeric species, binding
to Ab fibrils is favored by ~2.2RT. Consequently, the bind-
ing temperature, Tb, for the fibril is ~50 K higher than for
the Ab monomer.
It is known from experimental studies that the molecular
imaging probe FDDNP competes for the same Ab binding
sites as ibuprofen (21). Since FDDNP associates with Ab
fibrils with higher affinity than with other structural species
(54), one can assume that similar structural selectivity exists
for ibuprofen. These arguments are consistent with our simu-
lations, which offer a molecular explanation for the selec-
tivity of ibuprofen with respect to different structural Ab
species.
We have shown that there is a preference for ibuprofen to
bind to the N-terminal of Ab monomers. Analyzing the
number of contacts between ibuprofen and amino acid side
chains, <Cl(i)>, we found that the N-terminal forms about
twice as many interactions with ibuprofen as does the
C-terminal (Fig. 3). Because Ab monomers do not have
a stable native fold, the cooperativity arguments advanced
above cannot explain this preference. However, a plausible
explanation is provided by the ibuprofen ASA of residues.
In Fig. 3, we plot the average <ASA(i)> for residues i in
Ab monomers. It is seen that the N-terminal is more acces-
sible for ligands than the C-terminal. From Fig. 3, we
compute the total ASA of the N-terminal, <ASA(NT)> to
be ~1615 A˚2 (or 115 A˚2/residue). In contrast, the C-terminal
ASA, <ASA(CT)>, is considerably smaller (~980 A˚2 or
89 A˚2/residue). This variation in ASA along the Ab sequence
is consistent with the change in<Cl(i)>. Therefore, the ASA
of amino acids is a factor in binding ibuprofen to Ab mono-
mers, which is not the case for Ab fibrils. Taken together, our
Ibuprofen Binding to Ab Peptides 2077simulations suggest that the binding mechanisms for Ab
fibrils and monomers are different.
Plausible antiaggregation mechanism
of ibuprofen
It is useful to consider the simulations of ibuprofen binding
in the context of our previous studies of Ab aggregation. We
showed earlier that the primary aggregation interface in
Ab10–40 dimers involves the N-terminal sequence (residues
10–23) (34,45). This sequence region forms about twice as
many interpeptide side-chain contacts as the C-terminal. It
is intriguing that the N-terminal in Ab monomers also shows
the highest affinity for binding ibuprofen (Fig. 3). It is also
important that ibuprofen binding appears to have little
impact on the conformational ensemble of Ab monomers.
Therefore, ibuprofen is likely to interfere directly with
interpeptide interactions and destabilize the Ab aggregation
interface. The alternative antiaggregation mechanism, in
which changes in Ab structure make it less susceptible to
aggregation, is not supported by our findings.
Our previous simulations showed that the N-terminal is
also the primary aggregation interface in Ab10–40 fibril
growth (44). Furthermore, the CV edge has ~10-fold higher
affinity for binding incoming Ab peptides than the CX edge
(30,44). It is noteworthy that our current results show that
ibuprofen preferentially binds to the CV edge and localizes
within the CV groove. Therefore, one may suggest that
upon binding to the CV edge, ibuprofen directly interferes
with the deposition of incoming Ab peptides by destabilizing
peptide-fibril side-chain interactions.
The picture of the ibuprofen antiaggregation effect
described above is consistent with some experimental obser-
vations. For example, it has been shown that ibuprofen
reduces the number of Ab oligomers in mouse brain tissues
(18). Ibuprofen largely inhibits fibril assembly when coincu-
bated with ‘‘fresh’’ (not fibrillized) Ab peptides (21,23).
Moreover, ibuprofen at a concentration of 50 mM completely
blocks Ab fibril elongation (23). Because amyloid fibrils
grow via monomer addition to its edges (57–61), the fact
that ibuprofen is capable of blocking fibril elongation indi-
cates that it binds to the edges of the fibril. This conclusion
is consistent with our computational findings (Fig. 5 a).
Finally, we compare the numbers of binding sites in Ab
fibrils mapped from experimental data and our simulations.
It has been suggested that the molecular imaging probe
FDDNP uses the same binding sites as ibuprofen (54).
This observation raises the possibility of using FDDNP
binding sites in lieu of ibuprofen binding sites. For FDDNP,
two binding sites have been reported with high and low affin-
ities (54). It is important to note that the number of binding
sites/number of fibril peptides was estimated at ~3.5:10,000
(high affinity) and 7.1:10,000 (low affinity). A possible inter-
pretation of these findings is that FDDNP (and ibuprofen)
binds to the edges of Ab fibrils, which have different affini-ties for incoming ligands. This interpretation would be in line
with our in silico results described above.
CONCLUSIONS
Using REMD simulations and the implicit solvent model, we
examined binding of ibuprofen to Ab10–40 monomers and
fibrils. At sufficiently low temperatures, the bound ibuprofen
states are thermodynamically stable. We found that the
concave (CV) fibril edge reveals significantly higher affinity
for ibuprofen binding than the convex (CX) edge. Binding of
ibuprofen to Ab monomers appears to depend on the expo-
sure of amino acids to ligands and results in a smaller free-
energy gain than binding to fibrils. The difference in binding
free energies is apparently related to the presence of the
groove on the CV fibril edge, in which bound ibuprofen
tends to accumulate. The confinement effect produced by
the groove promotes the formation of large low-energy
ibuprofen clusters on the fibril surface. Due to the lack of
stable fold, large ibuprofen clusters do not occur on the Ab
monomer surface. Therefore, binding mechanisms for Ab
monomers and fibrils appear to be different.
It is important to note that ibuprofen shows a preference to
bind to those regions of Ab monomers (N-terminal) and
fibrils (the CV edge) that also represent the primary aggrega-
tion interfaces. Based on these findings and experimental
data, we have suggested a rationale for the ibuprofen antiag-
gregation effect. Because Ab10–40 appears to be an adequate
model for the Ab1–40 peptide (34), the results of our study
should be applicable to full-length Ab species.
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